| Stereotactic MR-guided Adaptive Radiation Therapy for Localized Prostate Cancer (NCT03961321) | Amsterdam UMC, location VUmc | 2016-08-25 |
| Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC (NCT02952469) | University of Iowa | 2016-07-14 |
| Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC (NCT02677376) | University of Wisconsin, Madison | 2016-06-27 |
| A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants (NCT02813408) | Janssen Pharmaceutica N.V., Belgium | 2016-05-03 |
| Tumor Hypoxia With HX4 PET in Several Diseases (NCT02584400) | Maastricht Radiation Oncology | 2016-05-01 |
| Effect of Intravenous Magnesium During Robot Assisted Prostatectomy (NCT02833038) | Ajou University School of Medicine | 2016-04-01 |
| Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection (NCT02647983) | Sunnybrook Health Sciences Centre | 2016-04-01 |
| Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer (NCT02710721) | Charite University, Berlin, Germany | 2016-04-01 |
| Engaging Newly Diagnosed Men About Cancer Treatment Options (NCT02668276) | University of Illinois at Chicago | 2016-04-01 |
| Second Primary Cancers in Patients With Castration Resistant Prostate Cancer (NCT02702908) | Bayer | 2016-03-15 |
| Evaluation of Safety and Efficacy of Estetrol in Healthy Men (NCT02718378) | Pantarhei Oncology B.V. | 2016-03-01 |
| Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg (NCT02712320) | Foresee Pharmaceuticals Co., Ltd. | 2016-02-01 |
| Determinants of Quality Of Life in AGEd Cancer Patients (NCT02672657) | Assistance Publique - Hôpitaux de Paris | 2016-02-01 |
| G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer (NCT02381236) | GenSpera, Inc. | 2016-02-01 |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs (NCT02621190) | Erasmus Medical Center | 2016-02-01 |
| Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET (NCT02631616) | Hadassah Medical Organization | 2016-02-01 |
| Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels (NCT02771769) | Chronix Biomedical Corporation | 2016-01-01 |
| Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery (NCT02600481) | Huadong Hospital | 2016-01-01 |
| A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (NCT02616185) | Pfizer | 2015-12-30 |
| Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (NCT02508636) | University of California, San Francisco | 2015-12-22 |
| Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer (NCT02651896) | Hospital Sirio-Libanes | 2015-12-20 |
| CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer (NCT02831920) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2015-12-07 |
| An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS (NCT02531516) | Aragon Pharmaceuticals, Inc. | 2015-11-19 |
| Targeted Fusion Biopsy of the Prostate (NCT02744534) | Emory University | 2015-11-01 |
| Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer (NCT02560051) | The University of Texas Health Science Center, Houston | 2015-11-01 |
| Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer (NCT02606123) | ESSA Pharmaceuticals | 2015-10-01 |
| A Registry of Participants With Prostate Cancer in Asia (NCT02546908) | Janssen Research & Development, LLC | 2015-09-09 |
| Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients (NCT02692976) | Radboud University Medical Center | 2015-09-01 |
| Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists (NCT02475057) | Rabin Medical Center | 2015-08-01 |
| Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial. (NCT02526602) | Tampere University Hospital | 2015-08-01 |
| Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer (NCT02362451) | National Cancer Institute (NCI) | 2015-07-10 |
| Feasibility Study for the Assessment of Sleep Quality in Men With Prostate Cancer Starting ADT (NCT02919904) | Vancouver Prostate Centre | 2015-07-01 |
| Gallium-68 Citrate PET Used in Prostate Cancer (NCT02391025) | Rahul Aggarwal | 2015-05-28 |
| Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 (NCT02362464) | National Cancer Institute (NCI) | 2015-05-12 |
| Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT (NCT02344667) | Juravinski Cancer Center | 2015-03-01 |
| Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer (NCT01962324) | Umeå University | 2015-03-01 |
| Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects (NCT02363855) | Bayer | 2015-02-23 |
| Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms (NCT02430649) | Fuda Cancer Hospital, Guangzhou | 2015-01-01 |
| Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC) (NCT02443571) | Blue Earth Diagnostics | 2015-01-01 |
| Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient (NCT02338700) | Fuda Cancer Hospital, Guangzhou | 2015-01-01 |
| SmartTarget THERAPY (NCT02290561) | University College, London | 2014-12-01 |
| Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer (NCT02334579) | Swedish Medical Center | 2014-12-01 |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT02257736) | Aragon Pharmaceuticals, Inc. | 2014-11-26 |
| Prostate Cancer Biobank (NCT04024475) | Swiss Cancer Institute | 2014-11-04 |
| Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (NCT02563691) | Sunnybrook Health Sciences Centre | 2014-11-01 |
| PRIME - PRostate Imaging for Margin Evaluation (NCT02151097) | Lightpoint Medical Limited | 2014-11-01 |
| Pilot Study of SBRT and CDX-1127 in Prostate Cancer (NCT02284971) | James Larner, MD | 2014-11-01 |
| Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer (NCT02453009) | Santa Chiara Hospital | 2014-10-01 |
| Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer (NCT02102477) | Olof Akre | 2014-10-01 |
| A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting (NCT02364531) | Janssen Inc. | 2014-09-30 |
| Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy (NCT02217566) | Janssen Research & Development, LLC | 2014-09-23 |
| Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy (NCT02631681) | Herlev Hospital | 2014-08-01 |
| Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma (NCT02234115) | Foresee Pharmaceuticals Co., Ltd. | 2014-08-01 |
| 18F-DCFBC PET/CT in Prostate Cancer (NCT02190279) | National Cancer Institute (NCI) | 2014-07-12 |
| A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT02123758) | Aragon Pharmaceuticals, Inc. | 2014-07-09 |
| MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound Guidance (NCT02233725) | University of British Columbia | 2014-07-01 |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts (NCT02266745) | Promontory Therapeutics Inc. | 2014-07-01 |
| Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy (NCT02153918) | National Cancer Institute (NCI) | 2014-05-31 |
| Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status (NCT02076503) | St. Olavs Hospital | 2014-04-01 |
| Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (NCT02043678) | Bayer | 2014-03-30 |
| Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone (NCT02023697) | Bayer | 2014-03-10 |
| A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) (NCT02034552) | Bayer | 2014-03-07 |
| Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (NCT02446444) | University of Sydney | 2014-03-01 |
| A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland (NCT02004418) | AHS Cancer Control Alberta | 2014-03-01 |
| High-dose Vitamin D Supplementation for ADT-induced Side Effects (NCT02064946) | University of Rochester | 2014-03-01 |
| Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (NCT02446405) | University of Sydney | 2014-03-01 |
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC (NCT01995058) | Exelixis | 2014-02-01 |
| Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer (NCT02125617) | Kristoffer Rohrberg | 2014-01-01 |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (NCT02014337) | Corcept Therapeutics | 2014-01-01 |
| Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases (NCT01934790) | Bayer | 2013-12-22 |
| Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer (NCT02079025) | Exact Imaging | 2013-12-01 |
| Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy (NCT01834001) | National Cancer Institute (NCI) | 2013-11-13 |
| Intrathecal Morphine in Robot-assisted Prostatectomy (NCT01991275) | Seoul National University Hospital | 2013-11-01 |
| A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (NCT01946204) | Aragon Pharmaceuticals, Inc. | 2013-10-14 |
| Japanese BAY88-8223 Monotherapy Phase II Study (NCT01929655) | Bayer | 2013-09-30 |
| Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC) (NCT02230059) | Janssen Research & Development, LLC | 2013-07-01 |
| Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer (NCT01857817) | Vicus Therapeutics | 2013-06-01 |
| Protection of Rectum From High Radiation Doses Using a Spacer (NCT01918605) | University of Oulu | 2013-06-01 |
| NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis (NCT01816048) | University of Wisconsin, Madison | 2013-05-01 |
| A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer (NCT01685489) | Bastyr University | 2013-05-01 |
| Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis (NCT01810770) | Bayer | 2013-03-26 |
| Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer (NCT02156414) | Javeriana University | 2013-03-01 |
| Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR (NCT02043184) | Michigan State University | 2013-03-01 |
| Focal Therapy for Prostate Cancer (NCT01802307) | University of Maryland, Baltimore | 2013-02-01 |
| Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer (NCT01796028) | Centre Antoine Lacassagne | 2013-01-01 |
| Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance (NCT02526797) | Herlev Hospital | 2013-01-01 |
| A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer (NCT01647789) | Novartis Pharmaceuticals | 2012-12-04 |
| Medico-economic Comparison of Robot-assisted Radical Prostatectomy Versus Radical Prostatectomy Via Laparotomy (NCT01577836) | Centre Hospitalier Universitaire de Nīmes | 2012-11-26 |
| First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (NCT01723475) | Bayer | 2012-11-02 |
| Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer (NCT01759836) | Asan Medical Center | 2012-10-01 |
| Curative Image Guided Radiotherapy for Prostate Cancer (NCT01550237) | St. Olavs Hospital | 2012-10-01 |
| [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers (NCT01717391) | John M. Buatti | 2012-10-01 |
| Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer (NCT01683994) | National Cancer Institute (NCI) | 2012-09-07 |
| Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer (NCT01420965) | Augusta University | 2012-09-01 |
| Atorvastatin Before Prostatectomy and Prostate Cancer (NCT01821404) | Tampere University Hospital | 2012-08-01 |
| Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer (NCT01576029) | Sanofi | 2012-08-01 |
| Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (NCT01618370) | Bayer | 2012-07-22 |
| Hemi-Ablative Prostate Brachytherapy (NCT02632669) | Royal Surrey County Hospital NHS Foundation Trust | 2012-07-06 |
| Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (NCT01605227) | Exelixis | 2012-07-01 |
| Ion Prostate Irradiation (NCT01641185) | Heidelberg University | 2012-05-01 |